Hims & Hers Health (HIMS) Stock Price, News & Analysis $8.80 +0.16 (+1.85%) (As of 05:32 PM ET) Add Compare Share Share Today's Range$8.64▼$8.8850-Day Range$5.76▼$8.9052-Week Range$5.65▼$12.34Volume1.49 million shsAverage Volume2.96 million shsMarket Capitalization$1.87 billionP/E RatioN/ADividend YieldN/APrice Target$12.08 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Hims & Hers Health MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside37.3% Upside$12.08 Price TargetShort InterestBearish12.75% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.12Based on 13 Articles This WeekInsider TradingSelling Shares$785,410 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.13) to ($0.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.14 out of 5 starsMedical Sector383rd out of 945 stocksOffices & Clinics Of Medical Doctors Industry2nd out of 6 stocks 3.3 Analyst's Opinion Consensus RatingHims & Hers Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.08, Hims & Hers Health has a forecasted upside of 37.3% from its current price of $8.80.Amount of Analyst CoverageHims & Hers Health has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted12.75% of the float of Hims & Hers Health has been sold short.Short Interest Ratio / Days to CoverHims & Hers Health has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Hims & Hers Health has recently increased by 2.06%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldHims & Hers Health does not currently pay a dividend.Dividend GrowthHims & Hers Health does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HIMS. Previous Next 2.8 News and Social Media Coverage News SentimentHims & Hers Health has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Hims & Hers Health this week, compared to 4 articles on an average week.Search Interest17 people have searched for HIMS on MarketBeat in the last 30 days. This is an increase of 55% compared to the previous 30 days.MarketBeat Follows7 people have added Hims & Hers Health to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Hims & Hers Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $785,410.00 in company stock.Percentage Held by Insiders31.63% of the stock of Hims & Hers Health is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.45% of the stock of Hims & Hers Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Hims & Hers Health are expected to grow in the coming year, from ($0.13) to ($0.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Hims & Hers Health is -51.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Hims & Hers Health is -51.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHims & Hers Health has a P/B Ratio of 5.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Hims & Hers Health Stock (NYSE:HIMS)Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.Read More HIMS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HIMS Stock News HeadlinesDecember 4, 2023 | marketbeat.comOzempic vs. Mounjaro:: Battle of the bulge (HIMS)The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs, led by the popularity of Ozempic. Celebrity usageNovember 29, 2023 | marketbeat.comHims & Hers earnings highlight expanded personalized treatmentsE-health and wellness platform operator Hims & Hers Inc. reported a stellar quarter of growth that highlighted its expanded line of personalized productsDecember 11, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.December 8, 2023 | americanbankingnews.comHims & Hers Health (NYSE:HIMS) Coverage Initiated by Analysts at Imperial CapitalDecember 7, 2023 | finance.yahoo.comInsider Sell Alert: COO Melissa Baird Sells 27,399 Shares of Hims & Hers Health Inc (HIMS)December 5, 2023 | markets.businessinsider.comBullish Outlook: Hims & Hers Health’s New Weight Loss Program Promises Long-Term GrowthDecember 5, 2023 | finance.yahoo.comInsider Sell: CEO Andrew Dudum of Hims & Hers Health Inc Cashes Out SharesDecember 5, 2023 | americanbankingnews.comHims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum Sells 24,300 Shares of StockDecember 11, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.December 4, 2023 | finance.yahoo.comHims & Hers Launches Holistic Weight Loss Program to Break the Endless Cycle of Weight Gain and LossDecember 2, 2023 | marketwatch.comHims Mental Health Review 2023: Results of Our Hands-On TestingNovember 30, 2023 | seekingalpha.comHims & Hers Health: What Would The Author Of 100 Baggers Say?November 27, 2023 | businessinsider.comWhy Hims & Hers won't prescribe Ozempic for now in its new weight-loss programNovember 16, 2023 | msn.comIs Hims & Hers Stock a Buy Now?November 10, 2023 | forbes.comHims & Hers HealthNovember 9, 2023 | markets.businessinsider.comTruist Financial Reaffirms Their Hold Rating on Hims & Hers Health (HIMS)November 9, 2023 | msn.comWall Street Analysts Predict a 70.23% Upside in Hims & Hers Health, Inc. (HIMS): Here's What You Should KnowNovember 8, 2023 | seekingalpha.comHims & Hers: The Most Undervalued Small Cap Stock I SeeNovember 8, 2023 | markets.businessinsider.comBuy Rating for Hims & Hers Health: Strong Performance and Substantial Growth PotentialNovember 7, 2023 | forbes.comHims Online Therapy Review 2023November 7, 2023 | barrons.comHims & Hers Health Sees Long-Term Tailwind from Weight Management BusinessNovember 7, 2023 | realmoney.thestreet.comHims & Hers Health's Outlook Starts to Firm UpNovember 7, 2023 | msn.comIs Hims & Hers Health Stock a Buy After Strong Earnings?November 7, 2023 | finance.yahoo.comHims & Hers Health, Inc. (NYSE:HIMS) Q3 2023 Earnings Call TranscriptNovember 7, 2023 | seekingalpha.comHims & Hers Q3 2023: Another Fantastic Quarter, We're Buying MoreNovember 6, 2023 | seekingalpha.comHims & Hers Health, Inc. 2023 Q3 - Results - Earnings Call PresentationNovember 6, 2023 | seekingalpha.comHims & Hers stock +6% after hours on raised revenue guidance, $50M share buybackSee More Headlines Receive HIMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hims & Hers Health and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/06/2023Today12/11/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Offices & clinics of medical doctors Sub-IndustryN/A SectorMedical Current SymbolNYSE:HIMS CUSIPN/A CIK1773751 Webwww.forhims.com Phone415-851-0195FaxN/AEmployees651Year FoundedN/APrice Target and Rating Average Stock Price Target$12.08 High Stock Price Target$18.00 Low Stock Price Target$9.00 Potential Upside/Downside+38.3%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($0.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-65,680,000.00 Net Margins-4.50% Pretax Margin-4.39% Return on Equity-11.22% Return on Assets-9.23% Debt Debt-to-Equity RatioN/A Current Ratio3.03 Quick Ratio2.76 Sales & Book Value Annual Sales$526.92 million Price / Sales3.52 Cash FlowN/A Price / Cash FlowN/A Book Value$1.50 per share Price / Book5.83Miscellaneous Outstanding Shares211,990,000Free Float144,940,000Market Cap$1.85 billion OptionableOptionable Beta0.78 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Andrew Dudum (Age 34)Co-Founder, Chairman & CEO Comp: $1.7MMr. Yemi Okupe (Age 37)Chief Financial Officer Comp: $804.05kMs. Melissa Baird (Age 45)Chief Operating Officer Comp: $917.67kMs. Irene A. Becklund (Age 38)Senior VP, Controller & Principal Accounting Officer Comp: $361.12kMs. Soleil Teubner Boughton (Age 44)Chief Legal Officer & Corporate Secretary Comp: $782.66kMr. Mike Chi (Age 43)Chief Marketing Officer Comp: $514.77kDr. Patrick Carroll M.D. (Age 65)Chief Medical Officer, Member of Medical Advisory Board & Director Comp: $27.03kMs. Khobi BrooklynChief Communications OfficerMs. Amee ParekhSenior Vice President of Human ResourcesDr. Peter Stahl M.D.Senior VP & Member of Medical Advisory BoardMore ExecutivesKey CompetitorsTeladoc HealthNYSE:TDOCPTC TherapeuticsNASDAQ:PTCTVeracyteNASDAQ:VCYTHarmony BiosciencesNASDAQ:HRMYProthenaNASDAQ:PRTAView All CompetitorsInsiders & InstitutionsMelissa BairdSold 9,133 sharesTotal: $82,379.66 ($9.02/share)Melissa BairdSold 9,133 sharesTotal: $80,461.73 ($8.81/share)Andrew DudumSold 24,300 sharesTotal: $219,429.00 ($9.03/share)Deutsche Bank AGSold 240,201 shares on 11/24/2023Ownership: 0.030%Graham Capital Management L.P.Bought 96,277 shares on 11/22/2023Ownership: 0.161%View All Insider TransactionsView All Institutional Transactions HIMS Stock Analysis - Frequently Asked Questions Should I buy or sell Hims & Hers Health stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hims & Hers Health in the last twelve months. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" HIMS shares. View HIMS analyst ratings or view top-rated stocks. What is Hims & Hers Health's stock price target for 2024? 9 brokers have issued twelve-month price objectives for Hims & Hers Health's shares. Their HIMS share price targets range from $9.00 to $18.00. On average, they predict the company's share price to reach $12.08 in the next year. This suggests a possible upside of 37.3% from the stock's current price. View analysts price targets for HIMS or view top-rated stocks among Wall Street analysts. How have HIMS shares performed in 2023? Hims & Hers Health's stock was trading at $6.41 at the start of the year. Since then, HIMS stock has increased by 37.3% and is now trading at $8.80. View the best growth stocks for 2023 here. When is Hims & Hers Health's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024. View our HIMS earnings forecast. How were Hims & Hers Health's earnings last quarter? Hims & Hers Health, Inc. (NYSE:HIMS) posted its quarterly earnings data on Monday, November, 6th. The company reported ($0.04) earnings per share for the quarter, missing analysts' consensus estimates of ($0.03) by $0.01. The business had revenue of $226.70 million for the quarter, compared to analyst estimates of $220.08 million. Hims & Hers Health had a negative net margin of 4.50% and a negative trailing twelve-month return on equity of 11.22%. Hims & Hers Health's revenue for the quarter was up 56.6% compared to the same quarter last year. During the same period last year, the firm earned ($0.09) EPS. What ETFs hold Hims & Hers Health's stock? ETFs with the largest weight of Hims & Hers Health (NYSE:HIMS) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), Global X Telemedicine & Digital Health ETF (EDOC), Alpha Architect U.S. Quantitative Momentum ETF (QMOM), Amplify Online Retail ETF (IBUY), Fidelity Digital Health ETF (FDHT) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).iShares U.S. Healthcare Providers ETF (IHF). Who are Hims & Hers Health's major shareholders? Hims & Hers Health's stock is owned by a number of institutional and retail investors. Top institutional investors include Institutional Venture Management XVI LLC (3.66%), Institutional Venture Management XV LLC (3.66%), Jupiter Asset Management Ltd. (0.69%), Charles Schwab Investment Management Inc. (0.60%), Northern Trust Corp (0.55%) and Federated Hermes Inc. (0.49%). Insiders that own company stock include Alex Bard, Andrew Dudum, David B Wells, David B Wells, Irene Becklund, Jack Abraham, Jules A Maltz, Lynne Chou O'keefe, Melissa Baird, Oluyemi Okupe, Patrick Harrison Carroll, Soleil Boughton and Spencer Lee. View institutional ownership trends. How do I buy shares of Hims & Hers Health? Shares of HIMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NYSE:HIMS) was last updated on 12/11/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hims & Hers Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.